Literature DB >> 23243289

FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report.

Michele S Redell1, Marcos J Ruiz, Robert B Gerbing, Todd A Alonzo, Beverly J Lange, David J Tweardy, Soheil Meshinchi.   

Abstract

Signal transducer and activator of transcription 3 (Stat3) and Stat5 are critical signaling intermediates that promote survival in myeloid leukemias. We examined Stat3 and Stat5 activation patterns in resting and ligand-stimulated primary samples from pediatric patients with acute myeloid leukemia. Phosphorylated Stats were measured by FACS before and after stimulation with increasing doses of granulocyte-colony stimulating factor or IL-6. We also measured positive and negative regulators of Stat signaling, and we compared the variation in multiple parameters to identify biologic relationships. Levels of constitutively phosphorylated Stats were variable and did not correlate with survival. In terms of induced phospho-Stats, 15 of 139 specimens (11%) phosphorylated Stat3 in response to moderate doses of both granulocyte-colony stimulating factor and IL-6. Compared with groups that were resistant to 1 or both ligands, this pattern of dual sensitivity was associated with a superior outcome, with a 5-year event-free survival of 79% (P = .049) and 5-year overall survival of 100% (P = .006). This study provides important and novel insights into the biology of Stat3 and Stat5 signaling in acute myeloid leukemia. Patterns of ligand sensitivity may be valuable for improving risk identification, and for developing new agents for individualized therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23243289      PMCID: PMC3575754          DOI: 10.1182/blood-2012-04-421925

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.

Authors:  Z Wen; Z Zhong; J E Darnell
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

2.  Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells.

Authors:  Pedro J Real; Angels Sierra; Ana De Juan; Jose C Segovia; Jose M Lopez-Vega; Jose L Fernandez-Luna
Journal:  Oncogene       Date:  2002-10-31       Impact factor: 9.867

3.  FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.

Authors:  Jessica A Pollard; Todd A Alonzo; Robert B Gerbing; William G Woods; Beverly J Lange; David A Sweetser; Jerald P Radich; Irwin D Bernstein; Soheil Meshinchi
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

4.  Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6.

Authors:  J J Schuringa; A T Wierenga; W Kruijer; E Vellenga
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

5.  JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.

Authors:  D P Steensma; R F McClure; J E Karp; A Tefferi; T L Lasho; H L Powell; G W DeWald; S H Kaufmann
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

6.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.

Authors:  F Hayakawa; M Towatari; H Kiyoi; M Tanimoto; T Kitamura; H Saito; T Naoe
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

7.  Proteolytic conversion of STAT3alpha to STAT3gamma in human neutrophils: role of granule-derived serine proteases.

Authors:  Takayuki Kato; Erina Sakamoto; Haruo Kutsuna; Akiko Kimura-Eto; Fumihiko Hato; Seiichi Kitagawa
Journal:  J Biol Chem       Date:  2004-05-15       Impact factor: 5.157

8.  Single cell profiling of potentiated phospho-protein networks in cancer cells.

Authors:  Jonathan M Irish; Randi Hovland; Peter O Krutzik; Omar D Perez; Øystein Bruserud; Bjørn T Gjertsen; Garry P Nolan
Journal:  Cell       Date:  2004-07-23       Impact factor: 41.582

9.  STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients.

Authors:  V Gouilleux-Gruart; F Gouilleux; C Desaint; J F Claisse; J C Capiod; J Delobel; R Weber-Nordt; I Dusanter-Fourt; F Dreyfus; B Groner; L Prin
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

10.  Increased expression of the differentiation-defective granulocyte colony-stimulating factor receptor mRNA isoform in acute myelogenous leukemia.

Authors:  S M White; E D Ball; W C Ehmann; A S Rao; D J Tweardy
Journal:  Leukemia       Date:  1998-06       Impact factor: 11.528

View more
  19 in total

1.  Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia.

Authors:  Xin Long; Yang Yu; Laszlo Perlaky; Tsz-Kwong Man; Michele S Redell
Journal:  Br J Haematol       Date:  2015-05-14       Impact factor: 6.998

2.  Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance.

Authors:  Alexandra M Stevens; Jennifer M Miller; Jaime O Munoz; Amos S Gaikwad; Michele S Redell
Journal:  Blood Adv       Date:  2017-08-01

3.  STAT3β is a tumor suppressor in acute myeloid leukemia.

Authors:  Petra Aigner; Tatsuaki Mizutani; Jaqueline Horvath; Thomas Eder; Stefan Heber; Karin Lind; Valentin Just; Herwig P Moll; Assa Yeroslaviz; Michael J M Fischer; Lukas Kenner; Balázs Győrffy; Heinz Sill; Florian Grebien; Richard Moriggl; Emilio Casanova; Dagmar Stoiber
Journal:  Blood Adv       Date:  2019-07-09

Review 4.  Twist as a new prognostic marker in hematological malignancies.

Authors:  F Norozi; A Ahmadzadeh; M Shahjahani; S Shahrabi; N Saki
Journal:  Clin Transl Oncol       Date:  2015-07-24       Impact factor: 3.405

5.  High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  George S Laszlo; Rhonda E Ries; Chelsea J Gudgeon; Kimberly H Harrington; Todd A Alonzo; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Soheil Meshinchi; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2014-03-24

Review 6.  Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.

Authors:  Alan S Gamis; Todd A Alonzo; John P Perentesis; Soheil Meshinchi
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

7.  Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.

Authors:  R Brown; S Yang; C Weatherburn; J Gibson; P J Ho; H Suen; D Hart; D Joshua
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

8.  Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidine.

Authors:  Eleftheria Lamprianidou; Chryssoula Kordella; Anastasiya Kazachenka; Emmanouela Zoulia; Elsa Bernard; Anastasia Filia; Stamatia Laidou; Panayiotis Garantziotis; Theodoros P Vassilakopoulos; Sotirios G Papageorgiou; Vassiliki Pappa; Athanasios G Galanopoulos; Nora Viniou; Evangelia Nakou; Lydia Kalafati; Anastasia Chatzidimitriou; George Kassiotis; Elli Papaemmanuil; Ioannis Mitroulis; Ioannis Kotsianidis
Journal:  Blood Adv       Date:  2021-01-12

9.  Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Alexandra M Stevens; Marcos J Ruiz; Robert B Gerbing; Todd A Alonzo; Alan S Gamis; Michele S Redell
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

10.  Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Aswathi A George; Helicia Paz; Fei Fei; Jonathan Kirzner; Yong-Mi Kim; Nora Heisterkamp; Hisham Abdel-Azim
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.